FINAL BILL REPORT

ESB 5375

This analysis was prepared by non-partisan legislative staff for the use of legislative members in their deliberations. This analysis is not a part of the legislation nor does it constitute a statement of legislative intent.

Sponsors: Senators Fain, Braun, Angel, Brown, Becker, O'Ban, Miloscia, Schoesler, Bailey, Sheldon, Warnick, King, Rivers, Fortunato, Rossi, Baumgartner, Wilson, Honeyford, Padden, Zeiger, Ranker, Darneille, Palumbo, Pedersen, Pearson, Frockt and Hasegawa.

Background: The cancer research endowment authority (Authority) was created in 2015 to develop and annually update a plan for the allocation of project funds. The Authority has a 13-member board of trustees with representatives of research universities, cancer research institutions, patient advocacy organizations, businesses engaged in commercialization of life sciences or cancer research, health care delivery systems, the Legislature, fund donors, and the public. The duties of the program administrator include: soliciting grants, gifts, and donations; managing funds; distributing grants; and implementing other activities directed by the Authority.

Senator Andy Hill served in the Senate from January 2011 until his death from lung cancer on October 31, 2016. Senator Hill served as the chair of the Senate Ways and Means Committee.

Summary: The name of the cancer research endowment authority is changed to the Andy Hill Cancer Research Endowment. It is clarified that expenditures to fund the program administrator do not require private matching funds. Data submitted by grant applicants is protected from public disclosure.

Votes on Final Passage:

Senate	48	0
Senate	49	0
Senate	48	0
House	94	1